Andromeda Biotech Acquires DiaPep277 Rights From Teva Pharmaceutical Industries Limited

24 Feb 2014

·www.biospace.com

CollaborateAcquisition

YAVNE, Israel, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Andromeda Biotech Ltd. announces that it entered into an agreement with Teva Pharmaceutical Industries Ltd. for the acquisition of Teva's rights for Andromeda's drug, DiaPep277®, for the treatment of Type Type 1 Diabetes. Help employers find you! Check out all the jobs and post your resume.

Organizations

Andromeda Biotech Ltd.

Andromeda Medizinische Systeme GmbH

American Type Culture Collection

[+1]

Indications

Diabetes Mellitus, Type 1

Targets

Drugs

DiaPep-277

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.